IRDiRC announces publication of a new manuscript, developed as part of the International Rare Disease Research Consortium (IRDiRC) N-of-1 Task Force: “Applying the IRDiRC N-of-1 Therapy Task Force Eligibility Criteria for Individualised Therapies – Use Case: Duchenne Muscular Dystrophy“. Nucleic acid-based therapies, including antisense oligonucleotides (ASOs), are opening new doors for the treatment of rare diseases. With over […]
Read More
This year’s conference theme is “Duchenne Care: 5 Years After the 2018 Care Considerations (Lancet)”, and will take place online on June 7 and 8, 2023, from 15:00 – 18:00 CEST. Particularly, the conference will include new publications, information about the implementation of these Care Considerations in different countries. Top experts in the field will […]
Read More